Cargando…
REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification
Many in silico predictors of genetic variant pathogenicity have been previously developed, but there is currently no standard application of these algorithms for variant assessment. Using 4,094 ClinVar-curated missense variants in clinically actionable genes, we evaluated the accuracy and yield of b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726608/ https://www.ncbi.nlm.nih.gov/pubmed/31484976 http://dx.doi.org/10.1038/s41598-019-49224-8 |
_version_ | 1783449103422717952 |
---|---|
author | Tian, Yuan Pesaran, Tina Chamberlin, Adam Fenwick, R. Bryn Li, Shuwei Gau, Chia-Ling Chao, Elizabeth C. Lu, Hsiao-Mei Black, Mary Helen Qian, Dajun |
author_facet | Tian, Yuan Pesaran, Tina Chamberlin, Adam Fenwick, R. Bryn Li, Shuwei Gau, Chia-Ling Chao, Elizabeth C. Lu, Hsiao-Mei Black, Mary Helen Qian, Dajun |
author_sort | Tian, Yuan |
collection | PubMed |
description | Many in silico predictors of genetic variant pathogenicity have been previously developed, but there is currently no standard application of these algorithms for variant assessment. Using 4,094 ClinVar-curated missense variants in clinically actionable genes, we evaluated the accuracy and yield of benign and deleterious evidence in 5 in silico meta-predictors, as well as agreement of SIFT and PolyPhen2, and report the derived thresholds for the best performing predictor(s). REVEL and BayesDel outperformed all other meta-predictors (CADD, MetaSVM, Eigen), with higher positive predictive value, comparable negative predictive value, higher yield, and greater overall prediction performance. Agreement of SIFT and PolyPhen2 resulted in slightly higher yield but lower overall prediction performance than REVEL or BayesDel. Our results support the use of gene-level rather than generalized thresholds, when gene-level thresholds can be estimated. Our results also support the use of 2-sided thresholds, which allow for uncertainty, rather than a single, binary cut-point for assigning benign and deleterious evidence. The gene-level 2-sided thresholds we derived for REVEL or BayesDel can be used to assess in silico evidence for missense variants in accordance with current classification guidelines. |
format | Online Article Text |
id | pubmed-6726608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67266082019-09-18 REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification Tian, Yuan Pesaran, Tina Chamberlin, Adam Fenwick, R. Bryn Li, Shuwei Gau, Chia-Ling Chao, Elizabeth C. Lu, Hsiao-Mei Black, Mary Helen Qian, Dajun Sci Rep Article Many in silico predictors of genetic variant pathogenicity have been previously developed, but there is currently no standard application of these algorithms for variant assessment. Using 4,094 ClinVar-curated missense variants in clinically actionable genes, we evaluated the accuracy and yield of benign and deleterious evidence in 5 in silico meta-predictors, as well as agreement of SIFT and PolyPhen2, and report the derived thresholds for the best performing predictor(s). REVEL and BayesDel outperformed all other meta-predictors (CADD, MetaSVM, Eigen), with higher positive predictive value, comparable negative predictive value, higher yield, and greater overall prediction performance. Agreement of SIFT and PolyPhen2 resulted in slightly higher yield but lower overall prediction performance than REVEL or BayesDel. Our results support the use of gene-level rather than generalized thresholds, when gene-level thresholds can be estimated. Our results also support the use of 2-sided thresholds, which allow for uncertainty, rather than a single, binary cut-point for assigning benign and deleterious evidence. The gene-level 2-sided thresholds we derived for REVEL or BayesDel can be used to assess in silico evidence for missense variants in accordance with current classification guidelines. Nature Publishing Group UK 2019-09-04 /pmc/articles/PMC6726608/ /pubmed/31484976 http://dx.doi.org/10.1038/s41598-019-49224-8 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Tian, Yuan Pesaran, Tina Chamberlin, Adam Fenwick, R. Bryn Li, Shuwei Gau, Chia-Ling Chao, Elizabeth C. Lu, Hsiao-Mei Black, Mary Helen Qian, Dajun REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title | REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title_full | REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title_fullStr | REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title_full_unstemmed | REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title_short | REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification |
title_sort | revel and bayesdel outperform other in silico meta-predictors for clinical variant classification |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726608/ https://www.ncbi.nlm.nih.gov/pubmed/31484976 http://dx.doi.org/10.1038/s41598-019-49224-8 |
work_keys_str_mv | AT tianyuan revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT pesarantina revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT chamberlinadam revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT fenwickrbryn revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT lishuwei revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT gauchialing revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT chaoelizabethc revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT luhsiaomei revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT blackmaryhelen revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification AT qiandajun revelandbayesdeloutperformotherinsilicometapredictorsforclinicalvariantclassification |